P A Pham

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. doi request reprint Emerging antiretroviral drug interactions
    Paul A Pham
    Division of Infectious Diseases, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA
    J Antimicrob Chemother 66:235-9. 2011
  2. pmc Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers
    P A Pham
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 53:4385-92. 2009
  3. doi request reprint Drug-drug interaction programs in clinical practice
    P A Pham
    Department of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA
    Clin Pharmacol Ther 83:396-8. 2008
  4. ncbi request reprint Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz
    Paul A Pham
    Johns Hopkins Hospital, Baltimore, MD, USA
    Antivir Ther 12:963-9. 2007
  5. doi request reprint Antiretroviral adherence and pharmacokinetics: review of their roles in sustained virologic suppression
    Paul A Pham
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    AIDS Patient Care STDS 23:803-7. 2009
  6. ncbi request reprint Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir
    Paul A Pham
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Acquir Immune Defic Syndr 45:201-5. 2007
  7. ncbi request reprint Tenofovir disoproxil fumarate for the treatment of HIV infection
    Paul A Pham
    Johns Hopkins University School of Medicine, Division of Infectious Diseases, 1830 E Monument St 443, Baltimore, MD 21287, USA
    Expert Opin Drug Metab Toxicol 2:459-69. 2006
  8. ncbi request reprint Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 E Monument St 443, Baltimore, MD 21287, USA
    Expert Rev Anti Infect Ther 1:415-22. 2003
  9. doi request reprint Tenofovir for the treatment of hepatitis B virus
    Alice M Jenh
    Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Pharmacotherapy 29:1212-27. 2009
  10. doi request reprint Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B
    Alice M Jenh
    Department of Pharmacy, The Johns Hopkins Hospital, 600 North Wolfe St, Carnegie 180, Baltimore, MD 21287, USA
    Expert Rev Anti Infect Ther 8:1079-92. 2010

Detail Information

Publications18

  1. doi request reprint Emerging antiretroviral drug interactions
    Paul A Pham
    Division of Infectious Diseases, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA
    J Antimicrob Chemother 66:235-9. 2011
    ..g. darunavir, raltegravir, maraviroc and etravirine)...
  2. pmc Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers
    P A Pham
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 53:4385-92. 2009
    ..Based on these interactions, we recommend low initial doses of rosuvastatin (5 mg) and atorvastatin (10 mg), with careful clinical monitoring of rosuvastatin- or atorvastatin-related adverse events when combined with TPV/r...
  3. doi request reprint Drug-drug interaction programs in clinical practice
    P A Pham
    Department of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA
    Clin Pharmacol Ther 83:396-8. 2008
    ....
  4. ncbi request reprint Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz
    Paul A Pham
    Johns Hopkins Hospital, Baltimore, MD, USA
    Antivir Ther 12:963-9. 2007
    ..Coadministration of these drugs might result in complex pharmacokinetic drug-drug interactions...
  5. doi request reprint Antiretroviral adherence and pharmacokinetics: review of their roles in sustained virologic suppression
    Paul A Pham
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    AIDS Patient Care STDS 23:803-7. 2009
    ....
  6. ncbi request reprint Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir
    Paul A Pham
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Acquir Immune Defic Syndr 45:201-5. 2007
    ..Because these agents, to various degrees, are substrates, inducers, and inhibitors of CYP450 3A4, there is concern for alterations in the pharmacokinetics (PK) of these combined agents...
  7. ncbi request reprint Tenofovir disoproxil fumarate for the treatment of HIV infection
    Paul A Pham
    Johns Hopkins University School of Medicine, Division of Infectious Diseases, 1830 E Monument St 443, Baltimore, MD 21287, USA
    Expert Opin Drug Metab Toxicol 2:459-69. 2006
    ..Because of its demonstrated efficacy and favourable safety profile, tenofovir disoproxil fumarate has quickly become a favoured nucleoside component of antiretroviral regimens for both treatment-naive and -experienced patients...
  8. ncbi request reprint Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 E Monument St 443, Baltimore, MD 21287, USA
    Expert Rev Anti Infect Ther 1:415-22. 2003
    ..Since its approval in October 2001, tenofovir disoproxil fumarate has quickly become a widely used component of antiretroviral regimens for both treatment-naive and -experienced patients...
  9. doi request reprint Tenofovir for the treatment of hepatitis B virus
    Alice M Jenh
    Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Pharmacotherapy 29:1212-27. 2009
    ..In addition, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other therapies for chronic HBV, including lamivudine and adefovir...
  10. doi request reprint Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B
    Alice M Jenh
    Department of Pharmacy, The Johns Hopkins Hospital, 600 North Wolfe St, Carnegie 180, Baltimore, MD 21287, USA
    Expert Rev Anti Infect Ther 8:1079-92. 2010
    ..Additionally, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other CHB therapies including lamivudine and adefovir...
  11. doi request reprint HIV infection-related tuberculosis: clinical manifestations and treatment
    Timothy R Sterling
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Clin Infect Dis 50:S223-30. 2010
    ..There are also differences in treatment of HIV infection-related TB because of overlapping drug toxicities and drug-drug interactions between antiretroviral therapy and anti-TB therapy...
  12. ncbi request reprint FDA approves Aptivus (tipranavir)
    Paul A Pham
    Hopkins HIV Rep 17:6-7. 2005
  13. ncbi request reprint Expanded drug access: etravirine (formerly TMC-125)
    Amanda R Colquitt
    Hopkins HIV Rep 19:8-10. 2007
  14. ncbi request reprint Drug profile: fosamprenavir (Lexiva)
    Paul A Pham
    Hopkins HIV Rep 15:10-1. 2003
  15. ncbi request reprint Drug profile: atazanavir (Reyataz, ATV)
    Paul A Pham
    Hopkins HIV Rep 15:4-5. 2003
  16. ncbi request reprint Expanded access drug profile: raltegravir (RAL, MK-0518)
    Amanda R Colquitt
    Hopkins HIV Rep 19:11-2. 2007
  17. ncbi request reprint Drug profile: telbivudine (Tyzeka)
    Paul A Pham
    Hopkins HIV Rep 19:7, 10. 2007
  18. ncbi request reprint Drug profile: enfuvirtide (Fuzeon, ENF, T-20)
    Paul A Pham
    Hopkins HIV Rep 15:1-2. 2003